Lilly planning submissions for Taltz in non-radiographic axial spondyloarthritis

Lilly said it plans to submit regulatory applications this year for Taltz ixekizumab to treat non-radiographic axial spondyloarthritis after the drug met the primary and all major secondary endpoints in the Phase III COAST-X trial.

Eli Lilly and Co. (NYSE:LLY) said Taltz met COAST-X's primary endpoints of a greater proportion of patients who achieved an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at week 16 and at week 52 vs. placebo. Major secondary endpoints included Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), low disease activity and sacroiliac joint inflammation...